Sleep Disturbances in Type 1 Diabetes and Mitigating Cardiovascular Risk DOI Creative Commons
Ghada Abu Irsheed, Pamela Martyn‐Nemeth, Kelly Glazer Baron

и другие.

The Journal of Clinical Endocrinology & Metabolism, Год журнала: 2024, Номер 109(12), С. 3011 - 3026

Опубликована: Авг. 6, 2024

Abstract Cardiovascular disease (CVD) is a major cause of morbidity and mortality in persons with type 1 diabetes (T1D). Despite control known cardiovascular (CV) risk factors better glycemic management, T1D still face heightened CVD risk, suggesting additional contributing factors. Sleep has recently been recognized as CV factor; however; the role sleep specifically population only started to emerge. Extensive evidence suggests that often encounter disturbances. This review aims comprehensively explore relationship between disturbances T1D, proposed possible mediators including control, which studied more extensively, less such blood pressure, lipid metabolism, weight management. Stress self-care behaviors likely also play CVD. The regarding interventions context mitigating these shown early, small-scale studies. assessments should be part standard care T1D. Further research focus on understanding impact mechanistic pathways developing T1D-specific reduce burden this population.

Язык: Английский

Consensus Guidelines for the Diagnosis and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Adult Asian Indians with Type 2 Diabetes DOI
Anoop Misra, Ashish Kumar, Mohammad Shafi Kuchay

и другие.

Diabetes & Metabolic Syndrome Clinical Research & Reviews, Год журнала: 2025, Номер 19(3), С. 103209 - 103209

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

1
Spatial histomorphometry reveals that local peripheral nerves modulate but are not required for skeletal adaptation to applied load in mice DOI Creative Commons
Alec T Beeve, Mohamed G. Hassan, Anna Li

и другие.

JBMR Plus, Год журнала: 2025, Номер unknown

Опубликована: Янв. 7, 2025

Mechanical loading is required for bone health and results in skeletal adaptation to optimize strength. Local nerve axons, particularly within the periosteum, may respond load-induced biomechanical biochemical cues. However, their role anabolic response remains controversial. We hypothesized that spatial alignment of periosteal nerves with sites formation would clarify this relationship. To achieve this, we developed RadialQuant, a custom tool histomorphometry. Tibiae control neurectomized (sciatic/femoral cut) pan-neuronal Baf53b-tdTomato reporter mice were loaded 5 days. Bone axon density then quantified simultaneously non-decalcified sections mid-diaphysis using RadialQuant. In animals, induced maximal at site peak compression, as has been reported previously. By contrast, did not significantly change overall density. Neurectomy depleted ~90% all near-total depletion on load-responsive surfaces. alone also caused de novo lateral aspect mid-diaphysis. neurectomy inhibit increases area, mineralizing surface, or rate. Rather, spatially redistributed toward tibial surface reduction posterolateral apex (-63%) enhancement (+1360%). Altogether, contributed comparable changes cortical area fraction. Our show local innervation modulates but applied load our model. This supports continued use weight-bearing exercise an effective strategy increase mass, even settings peripheral damage dysfunction.

Язык: Английский

Процитировано

0
The Effect of Zinc Supplementation on Glycemic, Weight, and Blood Pressure Control in Patients With Type 2 Diabetes Mellitus: A Double‐Blind Randomized Controlled Trial DOI Creative Commons
Mehrab Sayadi, Sara Javadpour Nowbandegani,

Fatemeh Balaghi Inalou

и другие.

Health Science Reports, Год журнала: 2025, Номер 8(1)

Опубликована: Янв. 1, 2025

ABSTRACT Backgrounds and Aims Type 2 diabetes its complications are assumed to be major public health problems globally. Zinc is one of the elements that play a part in insulin secretion signaling. Therefore, this study seeks answer following question: “What effects 220 mg zinc sulfate supplementation on weight, blood pressure, glycemic control patients with diabetes?”. Methods In randomized controlled double‐blind trial, 79 were allocated into two groups through permuted block randomization method. The group received capsules containing 50 zinc, placebo ingredient per week for 12 weeks. At start end treatment period, fasting glucose (FBG), glycated hemoglobin (HbA1c), level, waist circumference (WC), pressure measured. Results After weeks follow‐up, 72 completed study. There no significant differences before after intervention FBG, HbA1c, levels, WC between groups. Intragroup analysis showed weight body mass index increased group; however, these changes not comparison group. Also, diastolic significantly systolic both Conclusion Taking supplement twice did show benefit diabetes. Trial Registration This trial was registered Iranian Registry Clinical Trials (IRCT) website code number 29627 September 18, 2018.

Язык: Английский

Процитировано

0
Realigning diabetes regimens in older adults: a 4S Pathway to guide simplification and deprescribing strategies DOI
Medha Munshi, Anna R. Kahkoska, Joshua J. Neumiller

и другие.

The Lancet Diabetes & Endocrinology, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
Phenotypic Consensus Clustering and Treatment Heterogeneity Analysis in Critically Ill Patients with Comorbid Type 2 Diabetes Mellitus DOI Creative Commons
Xiujuan Chen, Jiaqi Sun, Huixian Li

и другие.

Archives of Medical Research, Год журнала: 2025, Номер 56(5), С. 103197 - 103197

Опубликована: Март 10, 2025

Язык: Английский

Процитировано

0
Resmetirom: The First Disease‐Specific Treatment for MASH DOI Creative Commons
Ali Mohamed Mousa,

Mervat Mahmoud,

Ghaida Mubarak AlShuraiaan

и другие.

International Journal of Endocrinology, Год журнала: 2025, Номер 2025(1)

Опубликована: Янв. 1, 2025

In 2023, the medical terminology for Nonalcoholic Fatty Liver Disease (NAFLD) and NA SteatoHepatitis (NASH) was updated to Metabolic Dysfunction‐Associated SteatoticLiver (MASLD) MA (MASH). This review highlights critical epidemiological, pathophysiological, therapeutic aspects of MASH, focusing on novel treatment option, resmetirom. Resmetirom, a thyroid hormone receptor‐beta (THR‐β) agonist, specifically targets liver function simulate localized hyperthyroidism, effectively reducing lipid accumulation fibrosis without systemic effects commonly associated with therapy. Clinical trials, particularly pivotal MAESTRO‐NASH trial, have demonstrated significant improvements in health metrics, achieving primary endpoints by resolving MASH worsening showing favorable safety profile. paper reviews mechanism action, efficacy, resmetirom, providing insight into its potential change landscape patients suffering from MASH.

Язык: Английский

Процитировано

0
Association between metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction subtypes and risk of colorectal cancer: A Prospective Cohort Study DOI
Yuan Li,

Xiangming Ma,

Jianguo Jia

и другие.

Clinics and Research in Hepatology and Gastroenterology, Год журнала: 2025, Номер unknown, С. 102573 - 102573

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
Insulin resistance and cancer: molecular links and clinical perspectives DOI
Alfredo Caturano, Enes Erul,

Roberto Nilo

и другие.

Molecular and Cellular Biochemistry, Год журнала: 2025, Номер unknown

Опубликована: Март 15, 2025

Язык: Английский

Процитировано

0
Dynamic Interference Testing Results with the Dexcom G6 Continuous Glucose Monitoring Device DOI

Nicole Thomé,

Hendrick Jensch,

Geethan Srikanthamoorthy

и другие.

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
Cemiplimab and diabetic ketoacidosis: a case report of a rare endocrinopathy associated with immune checkpoint inhibitors DOI Creative Commons
Anna Arecco, Cristian Petolicchio, Alessandro Pastorino

и другие.

Frontiers in Endocrinology, Год журнала: 2025, Номер 16

Опубликована: Март 25, 2025

Background Immune checkpoint inhibitors (ICIs) have revolutionised the cancer treatment landscape in last decades, improving outcome of several tumours, such as cutaneous squamous cell carcinoma (cSCC). ICIs are antibodies blocking immune pathways, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) with its ligand PD-L1. However, activation response can cause a broad range side effects, called immune-related adverse events (irAEs). Endocrine irAEs mainly represented by thyroid dysfunctions (thyrotoxicosis or hypothyroidism) hypophysitis, while adrenal insufficiency diabetes mellitus (DM) less common. Diabetic ketoacidosis (DKA) is potential life-threatening presentation ICI-induced insulin-dependent DM (IDDM). This report presents rare case DKA IDDM secondary to anti-PD-1 antibody cemiplimab therapy, this third described literature date. Case We describe 62-year-old female patient metastatic perianal who developed after fifth cycle cemiplimab. Hyperglycemia (1187 mg/dL), metabolic acidosis (pH 7.27) bicarbonate levels 11.9 mmol/L, arterial partial pressure carbon dioxide 25.7 mmHg increased anion gap (equal 25), hyperketonuria were present. Adequate glycaemic control was difficult maintain, intravenously therapy (insulin, sodium bicarbonate, potassium, fluids) required for long time. Subcutaneous basal-bolus insulin started, but scarce, also due concomitant administration prednisone hepatotoxicity, until subject’s death. Conclusion underlines importance awareness on endocrine ICIs, particularly DKA. A baseline assessment glycemia glycated hemoglobin mandatory, we recommend close monitoring glycemic trend over time during therapy. Patients their caregivers should be informed counselled recognise signs symptoms.

Язык: Английский

Процитировано

0